Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Casea S is a biodegradable, long-acting contraceptive implant designed to provide reversible contraception for 18–24 months. It releases etonogestrel, a well-characterized synthetic progestin used in existing contraceptive implants, via subdermal pellets. The unique feature of Casea S is its biodegradability—after the active period, the implant dissolves in the body and does not require surgical removal by a healthcare provider. This innovation aims to improve access and convenience for users, especially in settings where follow-up care may be limited. The product is currently being evaluated in Phase 1 clinical trials for pharmacokinetics, removability (if needed), safety, and tolerability[1][2][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Casea S.